Summary of Study ST001467
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000999. The data can be accessed directly via it's Project DOI: 10.21228/M8K10H This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001467 |
Study Title | Metabolites changes related to glucose-mediated energy production in chemotheraphy-induced cachexia |
Study Summary | Targeted metabolomics platforms included amino acids and metabolites related to glucose-mediated energy production. The targeted metabolome changed with chemotheraphy-induced cachexia, and the changes were reversed with potential treatment of the cachexia. .rdb files were included as raw data files where detailed information regarding MRM transitions and internal standards can be found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution because their peak intensities were too high. Thus their analysis was performed separately from other amino acids, and their rdb files were saved in separate rdb files. |
Institute | Asan Medical Center; University of Ulsan |
Last Name | Yoo |
First Name | Hyun Ju |
Address | 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea |
yoohyunju@amc.seoul.kr | |
Phone | 82-02-3010-4029 |
Submit Date | 2020-08-18 |
Raw Data Available | Yes |
Analysis Type Detail | LC-MS |
Release Date | 2020-09-21 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000999 |
Project DOI: | doi: 10.21228/M8K10H |
Project Title: | Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study |
Project Summary: | A multimodal approach was performed to investigate the effects of BST204 on the alleviation of chemotherapy-induced cachexia. The targeted metabolome changed with chemotheraphy-induced cachexia and the changes were reversed with potential treatment of the cachexia. |
Institute: | Asan Medical Center; University of Ulsan |
Last Name: | Yoo |
First Name: | Hyun Ju |
Address: | 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea |
Email: | yoohyunju@amc.seoul.kr |
Phone: | 82-02-3010-4029 |
Subject:
Subject ID: | SU001541 |
Subject Type: | Mammal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Group | Treatment | Sample Source |
---|---|---|---|---|
SA124328 | 5FU_2m | batch1 | 5FU | muscle |
SA124329 | 5FU_1m_1 | batch1 | 5FU | muscle |
SA124330 | 5FU_1m | batch1 | 5FU | muscle |
SA124331 | 5FU_3m | batch1 | 5FU | muscle |
SA124332 | 5FU_3m_2 | batch1 | 5FU | muscle |
SA124333 | 5FU_2m_1 | batch1 | 5FU | muscle |
SA124334 | 5FU_1m_2 | batch1 | 5FU | muscle |
SA124335 | 5FU_3m_1 | batch1 | 5FU | muscle |
SA124336 | 5FU_2m_2 | batch1 | 5FU | muscle |
SA124337 | 5FU_3p | batch1 | 5FU | plasma |
SA124338 | 5FU_1p_2 | batch1 | 5FU | plasma |
SA124339 | 5FU_2p | batch1 | 5FU | plasma |
SA124340 | 5FU_3p_2 | batch1 | 5FU | plasma |
SA124341 | 5FU_2p_2 | batch1 | 5FU | plasma |
SA124342 | 5FU_1p | batch1 | 5FU | plasma |
SA124343 | BST100_2m_2 | batch1 | BST204 | muscle |
SA124344 | BST200_3m_2 | batch1 | BST204 | muscle |
SA124345 | BST200_1m_2 | batch1 | BST204 | muscle |
SA124346 | BST100_3m_2 | batch1 | BST204 | muscle |
SA124347 | BST100_1m_2 | batch1 | BST204 | muscle |
SA124348 | BST100_2m | batch1 | BST204 | muscle |
SA124349 | BST200_1m | batch1 | BST204 | muscle |
SA124350 | BST100_3m | batch1 | BST204 | muscle |
SA124351 | BST200_1m_1 | batch1 | BST204 | muscle |
SA124352 | BST200_2m_1 | batch1 | BST204 | muscle |
SA124353 | BST200_3m_1 | batch1 | BST204 | muscle |
SA124354 | BST200_2m | batch1 | BST204 | muscle |
SA124355 | BST100_3m_1 | batch1 | BST204 | muscle |
SA124356 | BST200_2m_2 | batch1 | BST204 | muscle |
SA124357 | BST100_1m_1 | batch1 | BST204 | muscle |
SA124358 | BST100_2m_1 | batch1 | BST204 | muscle |
SA124359 | BST100_1m | batch1 | BST204 | muscle |
SA124360 | BST100_1p_2 | batch1 | BST204 | plasma |
SA124361 | BST200_1p | batch1 | BST204 | plasma |
SA124362 | BST100_1p | batch1 | BST204 | plasma |
SA124363 | BST100_2p | batch1 | BST204 | plasma |
SA124364 | BST200_2p_2 | batch1 | BST204 | plasma |
SA124365 | BST200_1p_2 | batch1 | BST204 | plasma |
SA124366 | BST100_2p_2 | batch1 | BST204 | plasma |
SA124367 | BST100_3p_2 | batch1 | BST204 | plasma |
SA124368 | BST200_3p_2 | batch1 | BST204 | plasma |
SA124369 | BST200_2p | batch1 | BST204 | plasma |
SA124370 | BST200_3p | batch1 | BST204 | plasma |
SA124371 | TB_2m_2 | batch1 | Control | muscle |
SA124372 | TB_1m_2 | batch1 | Control | muscle |
SA124373 | NTB_1m_2 | batch1 | Control | muscle |
SA124374 | TB_3m_2 | batch1 | Control | muscle |
SA124375 | NTB_2m_2 | batch1 | Control | muscle |
SA124376 | TB_3m | batch1 | Control | muscle |
SA124377 | NTB_2m | batch1 | Control | muscle |
SA124378 | NTB_1m_1 | batch1 | Control | muscle |
SA124379 | NTB_1m | batch1 | Control | muscle |
SA124380 | TB_1m_1 | batch1 | Control | muscle |
SA124381 | TB_3m_1 | batch1 | Control | muscle |
SA124382 | TB_2m_1 | batch1 | Control | muscle |
SA124383 | TB_1m | batch1 | Control | muscle |
SA124384 | NTB_2m_1 | batch1 | Control | muscle |
SA124385 | TB_2m | batch1 | Control | muscle |
SA124386 | TB_3p | batch1 | Control | plasma |
SA124387 | TB_3p_2 | batch1 | Control | plasma |
SA124388 | TB_2p | batch1 | Control | plasma |
SA124389 | NTB_1p | batch1 | Control | plasma |
SA124390 | NTB_2p | batch1 | Control | plasma |
SA124391 | TB_1p | batch1 | Control | plasma |
SA124392 | TB_1p_2 | batch1 | Control | plasma |
SA124393 | TB_2p_2 | batch1 | Control | plasma |
SA124394 | NTB_2p_2 | batch1 | Control | plasma |
SA124395 | NTB_1p_2 | batch1 | Control | plasma |
SA124396 | 5FU_5m | batch2 | 5FU | muscle |
SA124397 | 5FU_4m | batch2 | 5FU | muscle |
SA124398 | 5FU_6m | batch2 | 5FU | muscle |
SA124399 | 5FU_6m_1 | batch2 | 5FU | muscle |
SA124400 | 5FU_4m_2 | batch2 | 5FU | muscle |
SA124401 | 5FU_6m_2 | batch2 | 5FU | muscle |
SA124402 | 5FU_4m_1 | batch2 | 5FU | muscle |
SA124403 | 5FU_5m_1 | batch2 | 5FU | muscle |
SA124404 | 5FU_5m_2 | batch2 | 5FU | muscle |
SA124405 | 5FU_4p_2 | batch2 | 5FU | plasma |
SA124406 | 5FU_4p | batch2 | 5FU | plasma |
SA124407 | 5FU_6p_2 | batch2 | 5FU | plasma |
SA124408 | 5FU_6p | batch2 | 5FU | plasma |
SA124409 | 5FU_5p_2 | batch2 | 5FU | plasma |
SA124410 | 5FU_5p | batch2 | 5FU | plasma |
SA124411 | BST200_6m | batch2 | BST204 | muscle |
SA124412 | BST200_4m_2 | batch2 | BST204 | muscle |
SA124413 | BST200_6m_2 | batch2 | BST204 | muscle |
SA124414 | BST200_5m | batch2 | BST204 | muscle |
SA124415 | BST100_6m | batch2 | BST204 | muscle |
SA124416 | BST200_3m | batch2 | BST204 | muscle |
SA124417 | BST200_4m | batch2 | BST204 | muscle |
SA124418 | BST100_4m | batch2 | BST204 | muscle |
SA124419 | BST100_4m_1 | batch2 | BST204 | muscle |
SA124420 | BST100_6m_2 | batch2 | BST204 | muscle |
SA124421 | BST200_4m_1 | batch2 | BST204 | muscle |
SA124422 | BST200_5m_1 | batch2 | BST204 | muscle |
SA124423 | BST200_6m_1 | batch2 | BST204 | muscle |
SA124424 | BST100_5m | batch2 | BST204 | muscle |
SA124425 | BST100_5m_2 | batch2 | BST204 | muscle |
SA124426 | BST100_5m_1 | batch2 | BST204 | muscle |
SA124427 | BST100_6m_1 | batch2 | BST204 | muscle |
Collection:
Collection ID: | CO001536 |
Collection Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
Sample Type: | Blood (plasma) |
Collection Location: | muscle |
Storage Conditions: | -20℃ |
Treatment:
Treatment ID: | TR001556 |
Treatment Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
Treatment: | 5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally administerd in 5-day cycles. |
Treatment Compound: | 5-FU, BST204 |
Treatment Dose: | 5-FU (50 mg/kg), BST204 (100 or 200 mg/kg) |
Animal Endp Euthanasia: | study period was limited by day 11 |
Sample Preparation:
Sampleprep ID: | SP001549 |
Sampleprep Summary: | Metabolites related to glucose-mediated energy metabolism were extracted using LLE. Amino acids and bioamines were also extracted using LLE and underwent chemical derivatization with phenylisothiocyante. |
Processing Storage Conditions: | 4℃ |
Extraction Method: | Liquid Liquid Extraction (LLE) |
Combined analysis:
Analysis ID | AN002443 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1290 |
Column | Zorbax Eclipse XDB-C18 (100 x 2mm) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | ABI Sciex 5500 QTrap |
Ion Mode | POSITIVE |
Units | area ratio |
Chromatography:
Chromatography ID: | CH001788 |
Chromatography Summary: | Metabolites related to glucose-mediated metabolites were analyzed with LC-MS/MS (MRM) |
Instrument Name: | Agilent 1290 |
Column Name: | Synergi fusion RP (50 x 2mm) |
Column Temperature: | 23 |
Flow Gradient: | 0% B for 5 min, 0% to 90% B for 2 min, hold at 90% B for 8 min, 90% to 0% B for 1 min, and then hold at 0% B for 9 min |
Flow Rate: | 70 μL/min except for minutes 7 to 15, when it was 140 µL/min |
Internal Standard: | 13C5-glutamine |
Sample Injection: | 3 uL |
Solvent A: | 100% water; 5 mM ammonium acetate |
Solvent B: | 100% acetonitrile; 5 mM ammonium acetate |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH001789 |
Chromatography Summary: | Amino acids and bioamines were analyzed with LC-MS/MS (MRM) |
Instrument Name: | Agilent 1290 |
Column Name: | Zorbax Eclipse XDB-C18 (100 x 2mm) |
Column Temperature: | 50 |
Flow Gradient: | 0% B for 0.5 min, 0% to 95% B for 5 min, hold at 95% B for 1 min, 95% to 0% B for 0.5 min, then hold at 0% B for 2.5 min |
Flow Rate: | 500 μL/min |
Internal Standard: | 13C5-glutamine, serotonine-d4, dopamine-d4, tryptophan-d5, serine-d3, and lysine-d8 |
Sample Injection: | 3 uL |
Solvent A: | 100% water; 0.2% formic acid |
Solvent B: | 100% acetonitrile; 0.2% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002267 |
Analysis ID: | AN002443 |
Instrument Name: | ABI Sciex 5500 QTrap |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
MS Comments: | Amino acids and bioamines MRM mode Analyst 1.52 |
Ion Mode: | POSITIVE |